COVID-19: The Stories behind our vaccine development


Vaccine Development Story

Vaccine Development Story

From the beginning, Pfizer understood that defeating COVID-19 would require the power of science and unprecedented collaboration among scientists, companies and governments around the world.

Pfizer collaborated with the German biotechnology company BioNTech SE to jointly develop a COVID-19 vaccine using BioNTech’s messenger RNA (mRNA) vaccine program while simultaneously making self-funded investments to scale up Pfizer’s manufacturing capacity and distribution infrastructure. The goal was to bring a potential vaccine to the world faster than ever, but with Pfizer’s same scientific rigor and commitment to quality and safety.

In less than a year, we made the impossible possible, delivering in record time a breakthough COVID-19 vaccine granted a conditional marketing authorization, Emergency Use Authorization or temporary authorization in more than 50 countries worldwide. And we did it, without ever losing sight of the integrity, quality or safety of our work.

Watch how we collaborated at the speed of science with the global community on the 
​​​​​​​COVID-19 pandemic response.


Encouraging Collaboration

Encouraging Collaboration. Standing with Science.


Five-Point Plan for Unprecedented Collaboration​​​​​​​

Hospital Donations for COVID-19 Response​​​​​

Pfizer Stands With Science

As COVID-19 entered our collective global consciousness, Pfizer stood in solidarity with industry leaders and pledged to protect scientific integrity, building on our rich history in vaccine research and development.

Our five-point plan called upon members of the innovation ecosystem—including pharmaceutical companies, biotechs, government agencies and academic institutions—to work together to end this global health crisis.
​​​​​​​To complement this call for unprecedented industry collaboration, Pfizer also made a public pledge—along with eight other vaccine makers—to protect the time-tested scientific processes and regulatory protocols that have helped guide the safe delivery of medicines and vaccines to address patients’ unmet needs.

We made the early decision to begin clinical work and large-scale manufacturing at our own risk to ensure that product would be available immediately if our clinical trials prove successful, and an Emergency Use Authorization is granted.​​​​​​​​​​​​​​"

Dr. Albert Bourla

Chairman and Chief Executive Officer, Pfizer




Site Feature: Puurs, Belgium

Delivering breakthrough scientific advancements to patients worldwide depends on the success of Pfizer’s industry-leading supply chain and ability to solve logistical challenges quickly and safely.

When Pfizer’s Global Supply site in Puurs, Belgium, began preparing for COVID-19 vaccine production, we immediately invested in infrastructure to improve existing production facilities and add new production lines. Since then, our site colleagues at Puurs and in other manufacturing sites have been moving “at the speed of science,” to produce the vaccine.
Throughout 2021, Pfizer will continue collaborating with governments and nongovernmental organizations to help them vaccinate as many people around the world as possible, as quickly as possible.


Unleashing our science

Science can stop pandemics—it has before and it will again. The entire global scientific community is working together to beat the COVID-19 pandemic, because when science wins, we all win.

Watch why we believe that SCIENCE WILL WINTM.

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at


COVID-19 Updates 

Read the latest information about Pfizer’s COVID-19 vaccine on




Chairman and CEO Albert Bourla reflects on a year of breakthrough innovation at Pfizer

Bold Moves

Science illuminates a path forward for patients across the world


Courage, excellence, equity and joy guide all our endeavors


2020 by the numbers

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories